GO:0036503 ERAD quality control pathway: Protein Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036503 (ERAD quality control pathway) is the constitutive protein catabolic pathway that monitors ER-resident proteins, recognizes misfolded or aberrant species, retrotranslocates them to the cytosol, and targets them for degradation by the cytoplasmic proteasome.
• ERAD is functionally intertwined with the unfolded protein response (UPR), which transcriptionally expands ERAD capacity under ER stress.
• The SEL1L-HRD1 complex is the best-characterized mammalian ERAD branch, and its physiological importance has been demonstrated in vivo.
• ERAD handles both soluble and membrane ER proteins, with distinct substrate-processing routes and ubiquitin-ligase complexes such as RNF185/Membralin for membrane substrates.
• ERAD dysfunction is linked to cancer, neurodegeneration, metabolic disease, and secretory pathway disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are key tools for dissecting ERAD gene function and substrate specificity.
Description
The endoplasmic reticulum (ER) is the entry point for roughly one-third of the proteome, and its quality-control machinery must distinguish correctly folded proteins from aberrant species. GO:0036503, the ERAD quality control pathway, is the constitutive catabolic route that recognizes misfolded or aberrant ER-resident proteins and delivers them to the cytoplasmic proteasome for degradation. This pathway is not a single reaction but a coordinated sequence that includes substrate recognition, retrotranslocation (dislocation) from the ER to the cytosol, ubiquitination and other modifications required for substrate transfer, transport to the proteasome, and final proteolysis. Early studies on secreted and membrane protein quality control established the conceptual framework for ERAD, and subsequent work has defined its molecular components and regulatory logic. ERAD is closely coordinated with the unfolded protein response (UPR), which adjusts ERAD capacity according to the load of misfolded proteins. In mammals, the SEL1L-HRD1 complex is a central ERAD branch, and its physiological roles have been demonstrated through genetic models. Beyond soluble substrates, ER membrane proteins are handled by dedicated ubiquitin-ligase complexes such as RNF185/Membralin. Because ERAD influences the abundance of receptors, transporters, and secreted factors, it shapes cell signaling, differentiation, and stress responses. For researchers, GO:0036503 provides a framework for asking how individual ERAD components select substrates, how ubiquitination and extraction are coupled, and how ERAD failure contributes to disease. This article summarizes the QuickGO definition, the major stages and components, the genes involved, disease links, and the experimental and CRISPR-based methods used to study ERAD.
ERAD quality control pathway At A Glance
| GO ID | GO:0036503 |
|---|---|
| GO term | ERAD quality control pathway |
| Ontology | biological_process |
| Synonym | endoplasmic reticulum-associated degradation; endoplasmic reticulum-associated protein degradation pathway; ERAD pathway; ER-associated degradation pathway; protein degradation by ERAD |
| Major function | Constitutive recognition and proteasomal degradation of misfolded or aberrant ER-resident proteins |
| Key stages | Substrate recognition, retrotranslocation, ubiquitination, transport to the proteasome, degradation |
| Cellular location | Endoplasmic reticulum and cytosol, with delivery to the cytoplasmic proteasome |
| Representative complexes | SEL1L-HRD1, RNF185/Membralin, and other ERAD ubiquitin-ligase complexes |
| Crosstalk | Coordinated with the unfolded protein response (UPR) |
What Is GO:0036503?
GO:0036503 (ERAD quality control pathway) is the protein catabolic pathway that constitutively monitors and targets misfolded or aberrant endoplasmic reticulum (ER)-resident proteins for degradation by the cytoplasmic proteasome. It begins with recognition of the ER-resident protein, includes retrotranslocation (dislocation) of the protein from the ER to the cytosol, protein modifications necessary for correct substrate transfer (for example ubiquitination), transport of the protein to the proteasome, and ends with degradation of the protein by the cytoplasmic proteasome.
Why Is ERAD quality control pathway Important in Cell Biology?
ERAD quality control is essential because the ER must maintain a functional secretory proteome while removing potentially toxic misfolded species. The pathway determines the half-life of many ER-resident and secretory proteins, thereby influencing receptor availability, signal transduction, and metabolic homeostasis. Its coordination with the UPR allows cells to match degradation capacity to folding demand, and failure of this coordination is associated with human disease. Because ERAD substrates include clinically important proteins, the pathway is both a basic cell-biology topic and a potential therapeutic target.
• Maintains ER proteostasis by constitutively removing misfolded or aberrant ER-resident proteins.
• Prevents accumulation of aggregation-prone species that can contribute to neurodegeneration.
• Regulates abundance of secretory and membrane proteins, including receptors and transporters.
• Is transcriptionally and functionally coupled to the UPR under ER stress.
• Controls lipid and metabolic homeostasis through degradation of key ER enzymes and regulators.
• Provides a quality-control checkpoint for membrane proteins via dedicated ligase complexes such as RNF185/Membralin.
• Contributes to immune and inflammatory signaling by tuning ER-resident immune regulators.
• Is a determinant of cancer cell survival under proteotoxic stress.
• Offers a mechanistic framework for understanding genetic diseases caused by ERAD component mutations.
• Is a tractable target for CRISPR-based functional genomics and therapeutic discovery.
What Happens During ERAD quality control pathway?
Substrate recognition
In simple terms: The cell first spots a protein in the ER that is not folded correctly.
ERAD begins with recognition of misfolded or aberrant ER-resident proteins. This step involves chaperones and lectins that detect exposed hydrophobic patches or incomplete folding, as well as ERAD adaptors that engage specific substrates. Recognition is selective: correctly folded proteins are spared, while aberrant species are committed to degradation. The SEL1L-HRD1 complex is a major mammalian recognition and processing hub for soluble and membrane substrates.
Retrotranslocation (dislocation)
In simple terms: The flagged protein is pulled out of the ER into the cytosol.
After recognition, substrates are retrotranslocated (dislocated) from the ER lumen or membrane into the cytosol. This step requires a protein-conducting channel or extraction machinery and is coupled to the action of ATPases and ubiquitin-ligase complexes. For ER membrane proteins, the RNF185/Membralin ubiquitin-ligase complex participates in substrate processing and extraction. Retrotranslocation is a point of regulation because it determines which substrates successfully reach the cytosolic degradation machinery.
Ubiquitination and substrate modification
In simple terms: The protein gets tagged with ubiquitin so the proteasome can recognize it.
Substrates undergo ubiquitination and other modifications necessary for correct transfer to the cytosol. Ubiquitin-ligase complexes, including SEL1L-HRD1 and RNF185/Membralin, attach ubiquitin chains that serve as degradation signals. These modifications are not merely tags; they coordinate substrate extraction, solubility, and delivery to the proteasome. The type and length of ubiquitin chains can influence substrate fate and processing efficiency.
Transport to the proteasome
In simple terms: The tagged protein is moved to the proteasome, the cell's protein shredder.
After dislocation and ubiquitination, substrates are transported to the cytoplasmic proteasome. This step involves chaperones, ubiquitin-binding factors, and motor proteins that maintain substrate solubility and deliver them to the proteasome. The pathway ends with degradation of the protein by the cytoplasmic proteasome, completing the ERAD quality-control cycle.
Crosstalk with the unfolded protein response
In simple terms: When the ER is stressed, the cell makes more ERAD machinery.
ERAD is functionally coupled to the unfolded protein response (UPR), which senses ER stress and transcriptionally upregulates ERAD components to restore proteostasis. This crosstalk ensures that degradation capacity matches the load of misfolded proteins. The UPR also reshapes ER quality control more broadly, influencing folding, trafficking, and degradation decisions.
ER-associated RNA silencing
In simple terms: The ER can also reduce the production of problematic proteins by silencing their RNAs.
Beyond protein degradation, ER quality control includes ER-associated RNA silencing, which promotes ER quality control by reducing the load of problematic proteins. This mechanism complements ERAD by acting at the RNA level and highlights the layered nature of ER proteostasis.
Key Genes Involved in GO:0036503 ERAD quality control pathway
The following genes and protein complexes are central to ERAD quality control and are commonly studied in mechanistic and disease-focused research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SEL1L | Core adaptor of the SEL1L-HRD1 ERAD complex | Mammalian ERAD branch with demonstrated physiological roles |
| HRD1 (SYVN1) | ER membrane ubiquitin ligase in SEL1L-HRD1 | Central ERAD ligase for soluble and membrane substrates |
| RNF185 | ER membrane ubiquitin ligase | Works with Membralin in ER membrane protein quality control |
| TMEM259 (Membralin) | Adaptor/regulator in RNF185 complex | Required for degradation of ER membrane substrates |
| DERL1 | Retrotranslocation channel component | Facilitates dislocation of ERAD substrates |
| DERL2 | Retrotranslocation channel component | Participates in substrate extraction |
| VCP (p97) | AAA-ATPase for substrate extraction | Drives retrotranslocation and delivery to the proteasome |
| UBE2G2 | Ubiquitin-conjugating enzyme | Supports ERAD ubiquitination reactions |
| UBE2J1 | Ubiquitin-conjugating enzyme | Functions in ERAD ubiquitination |
| EDEM1 | ER lectin involved in substrate recognition | Recognizes misfolded glycoproteins for ERAD |
| EDEM2 | ER lectin involved in substrate recognition | Contributes to glycoprotein ERAD |
| EDEM3 | ER lectin involved in substrate recognition | Participates in glycoprotein ERAD |
| OS9 | ER lectin for substrate recognition | Binds misfolded glycoproteins |
| XTP3-B | ER lectin for substrate recognition | Assists in glycoprotein ERAD |
| BIP (HSPA5) | ER chaperone | Supports folding and ERAD substrate handling |
| HERPUD1 | ERAD-associated factor | Modulates ERAD and ER stress responses |
| ATF6 | UPR transcription factor | Regulates ERAD gene expression during ER stress |
How Is ERAD quality control pathway Regulated?
ERAD quality control is regulated at multiple levels. The unfolded protein response (UPR) senses ER stress and transcriptionally upregulates ERAD components to increase degradation capacity. The UPR also reshapes ER quality control by adjusting folding, trafficking, and degradation programs. In mammals, the SEL1L-HRD1 complex is a key regulated node, and its activity is tuned to physiological demands. ER-associated RNA silencing provides an additional layer of regulation by reducing the synthesis of problematic proteins. Together, these mechanisms allow cells to match ERAD activity to the load of misfolded proteins and to metabolic or secretory needs.
ERAD quality control pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SEL1L | Metabolic and secretory disease biology | Knockout and knock-in mouse or cell models |
| HRD1 (SYVN1) | ERAD dysfunction and proteotoxic stress | CRISPR knockout cell lines |
| RNF185 | Membrane protein quality control disorders | Knockout and tagged knock-in models |
| TMEM259 (Membralin) | ER membrane protein degradation defects | Knockout and overexpression models |
| VCP (p97) | Protein aggregation and neurodegeneration | Point-mutation and knockout models |
ERAD dysfunction in cancer
Cancer cells often experience high proteotoxic and secretory stress, and ERAD activity can influence their survival and proliferation. Because ERAD controls the abundance of receptors and signaling proteins, its dysregulation may alter oncogenic pathways. Targeting ERAD components is therefore being explored as a strategy to exploit proteostatic vulnerabilities in tumors.
ERAD and neurodegeneration
Defective ER quality control contributes to the accumulation of aggregation-prone proteins in neurodegenerative conditions. ERAD helps clear misfolded ER-resident and secretory proteins, and its failure can exacerbate ER stress and neuronal dysfunction. The crosstalk between ERAD and the UPR is particularly relevant in chronic stress states.
ERAD in metabolic and secretory disease
The SEL1L-HRD1 complex regulates metabolic and secretory pathways in mammals, and its dysfunction has been linked to metabolic disease phenotypes. ERAD also influences the processing of secreted factors and membrane transporters, which can affect systemic homeostasis. These findings position ERAD as a contributor to both rare genetic disorders and common metabolic conditions.
ERAD and membrane protein quality control disorders
Membrane protein quality control by the RNF185/Membralin complex is important for ER homeostasis, and its impairment can affect membrane protein trafficking and function. Because many disease-associated proteins are membrane proteins, defects in this branch may contribute to diverse pathologies. Studying these complexes helps clarify genotype-phenotype relationships in ER quality-control disorders.
From ERAD quality control pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for ERAD of a specific substrate? | CRISPR knockout cell line |
| Does a disease-associated variant alter ERAD activity? | Point-mutation knock-in cell line |
| Where and when is an ERAD component expressed? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of an ERAD component enhance substrate degradation? | Overexpression cell model |
| Which substrates depend on a specific ERAD branch? | Knockout plus proteomics or substrate reporter |
| Does ERAD inhibition alter drug sensitivity? | Knockout or point-mutation models with drug treatment |
How to Study the ERAD quality control pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance and UPR/ERAD gene expression | ER stress response profiling |
| Proteomics | Protein abundance and turnover | Substrate identification and degradation kinetics |
| Cycloheximide chase | Protein stability over time | ERAD substrate half-life measurement |
| Ubiquitination assay | Ubiquitin conjugation on substrates | ERAD ligase activity assessment |
| Fluorescence imaging | Localization and dynamics of ERAD components | Retrotranslocation and trafficking studies |
| CRISPR knockout screen | Genes required for ERAD or ER stress survival | Functional genomics of ERAD |
| Bioinformatics analysis | Pathway enrichment and candidate prioritization | Interpretation of ERAD screen and omics data |
Transcriptomic and RNA-level methods
RNA-seq and related transcriptomic approaches can measure UPR and ERAD gene expression changes under ER stress or genetic perturbation. ER-associated RNA silencing can be studied by profiling RNA stability and small RNA pathways at the ER. These methods help define how ERAD capacity is transcriptionally regulated.
Proteomic and degradation assays
Proteomics and pulse-chase degradation assays measure substrate turnover and identify ERAD-dependent proteins. Cycloheximide chase and ubiquitination assays can resolve specific steps such as dislocation and ubiquitination. These approaches are essential for assigning substrates to specific ERAD branches.
Imaging and localization
Fluorescence imaging of tagged ERAD components and substrates reveals their localization and dynamics within the ER and cytosol. Live-cell imaging can capture retrotranslocation and delivery to the proteasome. Tagged knock-in models are particularly useful for physiological localization studies.
Genetic and CRISPR screens
CRISPR knockout and library screens can identify genes required for ERAD of specific substrates or for ER stress survival. These screens connect ERAD components to cellular phenotypes and disease-relevant pathways. Bioinformatics analysis of screen data helps prioritize candidate ERAD regulators.
How CRISPR Can Be Used to Study GO:0036503 ERAD quality control pathway
Knockout
CRISPR knockout of ERAD genes such as SEL1L, HRD1, RNF185, or TMEM259 allows researchers to test whether a component is required for degradation of a specific substrate. Knockout models are also used to assess ER stress sensitivity and metabolic phenotypes. These models provide clean loss-of-function evidence for ERAD gene function.
Point Mutation
Point-mutation knock-in can model disease-associated variants or catalytically dead enzymes to separate enzymatic activity from scaffolding functions. Such models help determine whether a specific residue is required for substrate recognition, ubiquitination, or extraction. They are valuable for linking genotype to ERAD activity.
Knock-in
Tagged knock-in of ERAD genes enables physiological expression of fluorescent or epitope-tagged proteins for localization and interaction studies. Knock-in of reporter substrates can provide sensitive readouts of ERAD flux. These models preserve endogenous regulation and are useful for in vivo studies.
Overexpression
Overexpression of ERAD components or substrates can enhance or saturate the pathway, revealing rate-limiting steps and substrate preferences. Overexpression models are useful for biochemical purification and structural studies. They complement loss-of-function approaches by testing sufficiency.
How EDITGENE Supports ERAD quality control pathway Research
Researchers studying ERAD quality control pathway-related genes often need to determine whether a candidate gene is causally involved in substrate recognition, retrotranslocation, ubiquitination, or degradation, and whether a disease-associated variant alters this activity. EDITGENE provides CRISPR-based cell models and screening services designed to answer these questions with reproducible, publication-ready data.
Contact EDITGENE today to design your custom CRISPR model for ERAD quality control pathway research.
Frequently Asked Questions About ERAD quality control pathway
What is GO:0036503 ERAD quality control pathway?
GO:0036503 is the biological process that constitutively monitors and targets misfolded or aberrant ER-resident proteins for degradation by the cytoplasmic proteasome, including recognition, retrotranslocation, ubiquitination, transport, and degradation.
What genes are involved in ERAD quality control pathway?
Key genes include SEL1L, HRD1 (SYVN1), RNF185, TMEM259 (Membralin), DERL1, DERL2, VCP (p97), EDEM1-3, OS9, XTP3-B, BIP (HSPA5), and HERPUD1.
How is ERAD quality control pathway related to the unfolded protein response?
ERAD is functionally coupled to the UPR, which senses ER stress and transcriptionally upregulates ERAD components to restore proteostasis.
What are the main steps of ERAD quality control pathway?
The main steps are substrate recognition, retrotranslocation (dislocation), ubiquitination and modification, transport to the proteasome, and degradation by the cytoplasmic proteasome.
Which diseases are linked to ERAD quality control pathway dysfunction?
ERAD dysfunction has been linked to cancer, neurodegeneration, metabolic and secretory disease, and membrane protein quality-control disorders.
What is the role of SEL1L-HRD1 in ERAD?
SEL1L-HRD1 is a central mammalian ERAD complex that recognizes and processes substrates for degradation, with demonstrated physiological roles in vivo.
How do researchers study ERAD quality control pathway?
Researchers use RNA-seq, proteomics, cycloheximide chase, ubiquitination assays, imaging, and CRISPR screens to study ERAD.
Can CRISPR knockout be used to study ERAD genes?
Yes, CRISPR knockout of ERAD genes such as SEL1L, HRD1, RNF185, and TMEM259 is widely used to test substrate degradation and stress phenotypes.
What is the difference between ERAD and ER-associated RNA silencing?
ERAD degrades misfolded proteins, while ER-associated RNA silencing reduces the production of problematic proteins at the RNA level to support ER quality control.
Why is ERAD quality control pathway important for cell survival?
ERAD prevents accumulation of toxic misfolded proteins and regulates the abundance of secretory and membrane proteins, which is essential for proteostasis and cell survival.
Conclusion
GO:0036503 (ERAD quality control pathway) is a constitutive and essential protein degradation system that recognizes misfolded or aberrant ER-resident proteins and delivers them to the cytoplasmic proteasome through retrotranslocation, ubiquitination, and transport steps. Its coordination with the UPR and its specialized branches, such as SEL1L-HRD1 and RNF185/Membralin, make it a central node in ER proteostasis and a contributor to human disease. Continued research using CRISPR models, proteomics, and functional screens will clarify how ERAD selects substrates and how its dysfunction can be targeted therapeutically.
References
- 1. Hwang J et al.. 2018. Quality Control in the Endoplasmic Reticulum: Crosstalk between ERAD and UPR pathways.. Trends Biochem Sci 43(8):593-605 PMID: 30056836
- 2. Wiseman RL et al.. 2022. Reshaping endoplasmic reticulum quality control through the unfolded protein response.. Mol Cell 82(8):1477-1491 PMID: 35452616
- 3. Wang HH et al.. 2025. SEL1L-HRD1-mediated ERAD in mammals.. Nat Cell Biol 27(7):1063-1073 PMID: 40562846
- 4. Sun Z et al.. 2019. Protein quality control in the secretory pathway.. J Cell Biol 218(10):3171-3187 PMID: 31537714
- 5. Christianson JC et al.. 2023. Mechanisms of substrate processing during ER-associated protein degradation.. Nat Rev Mol Cell Biol 24(11):777-796 PMID: 37528230
- 6. Efstathiou S et al.. 2022. ER-associated RNA silencing promotes ER quality control.. Nat Cell Biol 24(12):1714-1725 PMID: 36471127
- 7. van de Weijer ML et al.. 2020. Quality Control of ER Membrane Proteins by the RNF185/Membralin Ubiquitin Ligase Complex.. Mol Cell 79(5):768-781.e7 PMID: 32738194
- 8. Needham PG et al.. 2013. How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: the early history of ERAD.. Biochim Biophys Acta 1833(11):2447-57 PMID: 23557783
